Source-grounded facts extracted from Summit Therapeutics Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Summit Therapeutics Inc. reported financial results for the first quarter ended March 31, 2026.
“On April 30, 2026, Summit Therapeutics Inc. (the “Company”) issued a press release announcing its financial results and operational progress for the first quarter ended March 31, 2026.”
Ujwala Mahatme resigned as Director at Summit Therapeutics Inc..
“Effective June 12, 2024, Ujwala Mahatme informed Summit Therapeutics Inc. (the “Company”) that she was resigning from her role as a member of the Board of Directors (the “Board”) of the Company, and from each committee of the Board, to focus on her increasing professional commitments outside the Company.”
Summit Therapeutics Inc. entered into Distribution Agreement with J.P. Morgan Securities LLC valued at up to $90,000,000 (effective 2024-05-13).
“On May 13, 2024, Summit Therapeutics Inc. (the “Company”) entered into a distribution agreement (the “Distribution Agreement”) with J.P. Morgan Securities LLC (“Sales Agent”), as sales agent, pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, shares of the Company’s common stock, par value $0.01 per share, having an aggregate offering price of up to $90,000,000 (the “Shares”).”
Summit Therapeutics Inc. reported financial results for the first quarter ended March 31, 2024.
“On May 1, 2024, Summit Therapeutics Inc. (the “Company”) issued a press release announcing its financial results and operational progress for the first quarter ended March 31, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.